Orthocell Ltd (ASX:OCC, OTC:ORHHF), a regenerative medicine company, has appointed highly regarded healthcare executive John Van Der Wielen as independent non-executive chairman.
Van Der Wielen brings 35 years of global experience in wealth management, private banking, investments and health insurance, including considerable experience in corporate strategy, international growth initiatives, M&A transactions and engaging strategic investors.
He has successfully navigated diverse industries, including healthcare, financial services and large investment portfolios.
Globally recognised executive
“We are delighted to welcome John to the Orthocell board,” Orthocell managing director Paul Anderson said.
“He is a globally recognised executive with a passion for supporting innovative life science companies growing into significant international success stories and for enhancing Australia’s capacity to translate local innovations into products that make a difference to clinical practice and patients’ lives.
“John is a dynamic and collaborative leader bringing significant expertise in corporate strategy, international growth, institutional and strategic investor engagement and M&A transactions.
“John’s broad experience will play an important role in the next growth phase at Orthocell and I am thrilled to be working alongside him, to advance the commercialisation of our promising products and pipeline.”
Dr Stewart Washer, who has served as the executive chairman since April 2014, will transition to the role of executive director while continuing his valued association with Orthocell.
The addition of Van Der Wielen to Orthocell's leadership team follows the recent appointment of globally recognised healthcare executive Dr Ravi Thadhani to the Orthocell board.
Strengthened leadership capabilities
The company is confident these strategic appointments will strengthen its leadership capabilities as it advances towards the development and commercialisation of its innovative medical devices and cellular therapies.
Supported by an experienced senior advisory team and an advanced regenerative medicine portfolio, Orthocell is well-positioned to drive its products into global markets.
The company focuses on developing cutting-edge treatments for tendon, cartilage and soft tissue injuries, leveraging its proprietary CellGro® platform.
The appointment of Van Der Wielen underscores Orthocell's commitment to accessing industry expertise and accelerating its growth trajectory.
This approach to regenerative medicine offers promising prospects for addressing unmet medical needs and improving patient outcomes worldwide.
“I am very excited to be joining the senior leadership team at Orthocell at this pivotal stage in the company’s development,” Van Der Wielen said.
“I have been monitoring the company’s significant progress including its recent landmark licensing deal with BioHorizons.
“I believe Orthocell is now extremely well placed to drive shareholder value by actively supporting distribution partners to ramp up sales in existing and additional international markets and to advance the commercialisation of its truly unique regenerative medicine portfolio.”
About Orthocell
Orthocell Limited is a regenerative medicine company dedicated to developing unique medical devices and cellular therapies.
With a focus on tendon, cartilage and soft tissue injuries, the company uses its proprietary CellGro® platform to provide effective treatment options.
With a strong advisory team and an advanced portfolio, Orthocell is poised to drive its products into global markets.